Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis: Sebi probes...

    Fortis: Sebi probes insider trading violation, other regulatory lapses

    Written by Ruby Khatun Khatun Published On 2018-05-23T10:30:30+05:30  |  Updated On 23 May 2018 10:30 AM IST
    Fortis: Sebi probes insider trading violation, other regulatory lapses

    New Delhi: Regulator Sebi is probing suspected insider trading by some institutional investors and other regulatory lapses at Fortis Healthcare amid a takeover battle and boardroom upheaval at the hospital chain, officials said.


    Apart from the Sebi probe that also includes an investigation into suspected disclosure lapses, the Serious Fraud Investigation Office (SFIO) and registrar of companies are also looking into alleged financial irregularities at Fortis and other promoter group entities including Religare, they added.


    Fortis is in the midst of a heated takeover battle with five entities bidding for the company along with a upheaval at the boardroom, wherein several directors have been stepping down.


    There were five suitors in the race for Fortis, including TPG-Manipal combine, Malaysia's IHH Healthcare and KKR-backed Radiant Life Care, which gave binding offers. However, China's Fosun Healthcare did not make a binding bid for the company.


    Besides, three directors have already resigned ahead of a shareholder vote on Tuesday to decide their future.


    The Securities and Exchange Board of India (Sebi) had first begun the investigation in February following reports that financial irregularities emerged at Fortis. The company was asked to furnish information and documents sought by the regulator.


    The development came against the backdrop of reports that Fortis' promoters -Malvinder Singh and Shivinder Singh - took at least USD 78 million (Rs 550 crore) out of the company without any board approval about a year ago.

    financial irregularitiesFortisFortis Healthcareinstitutional investorsinvestigationMalvinder Singhprobesregulatory lapsesReligareSEBISecurities and Exchange Board of IndiaSerious Fraud Investigation OfficeSFIOShivinder SinghTakeover Battletrading violation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok